Movement Alert｜Alebund Pharmaceuticals-B Falls 8.32% in Regular Trading, Post-IPO Correction Extends After First-Day Doubling

Market Focus07-06

On July 6, Alebund Pharmaceuticals-B (09637.HK) declined 8.32% in regular trading, trading at 28.22 HKD/share, with turnover of approximately 2 million HKD.

The decline represents a continuation of post-IPO volatility. The company listed on the Hong Kong Stock Exchange on June 29 at an offer price of 22.60 HKD, surging 103.54% on its debut to close at 46.00 HKD. The stock subsequently experienced a sharp correction, falling over 50% intraday on July 2 before rebounding approximately 18.75% on July 3. Notable institutional support emerged on listing day, with Singapore's GIC increasing its stake by 872,000 shares at 44.08 HKD each, and LAV Asset Management purchasing 450,000 shares at 45.06 HKD, totaling approximately 58.72 million HKD in combined investment.

Alebund Pharmaceuticals is a biopharmaceutical company focused on kidney disease therapies. Its core product AP301, an oral phosphate binder for hyperphosphatemia, has completed China Phase III registration trials and is expected to file for NDA approval in the near term.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108778007?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108778007","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Alebund Pharmaceuticals-B Falls 8.32% in Regular Trading, Post-IPO Correction Extends After First-Day Doubling","media":"Market Focus","content":"<p><p>On July 6, Alebund Pharmaceuticals-B (09637.HK) declined 8.32% in regular trading, trading at 28.22 HKD/share, with turnover of approximately 2 million HKD.</p><p>The decline represents a continuation of post-IPO volatility. The company listed on the Hong Kong Stock Exchange on June 29 at an offer price of 22.60 HKD, surging 103.54% on its debut to close at 46.00 HKD. The stock subsequently experienced a sharp correction, falling over 50% intraday on July 2 before rebounding approximately 18.75% on July 3. Notable institutional support emerged on listing day, with Singapore's GIC increasing its stake by 872,000 shares at 44.08 HKD each, and LAV Asset Management purchasing 450,000 shares at 45.06 HKD, totaling approximately 58.72 million HKD in combined investment.</p><p>Alebund Pharmaceuticals is a biopharmaceutical company focused on kidney disease therapies. Its core product AP301, an oral phosphate binder for hyperphosphatemia, has completed China Phase III registration trials and is expected to file for NDA approval in the near term.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Alebund Pharmaceuticals-B Falls 8.32% in Regular Trading, Post-IPO Correction Extends After First-Day Doubling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Alebund Pharmaceuticals-B Falls 8.32% in Regular Trading, Post-IPO Correction Extends After First-Day Doubling\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-06 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 6, Alebund Pharmaceuticals-B (09637.HK) declined 8.32% in regular trading, trading at 28.22 HKD/share, with turnover of approximately 2 million HKD.</p><p>The decline represents a continuation of post-IPO volatility. The company listed on the Hong Kong Stock Exchange on June 29 at an offer price of 22.60 HKD, surging 103.54% on its debut to close at 46.00 HKD. The stock subsequently experienced a sharp correction, falling over 50% intraday on July 2 before rebounding approximately 18.75% on July 3. Notable institutional support emerged on listing day, with Singapore's GIC increasing its stake by 872,000 shares at 44.08 HKD each, and LAV Asset Management purchasing 450,000 shares at 45.06 HKD, totaling approximately 58.72 million HKD in combined investment.</p><p>Alebund Pharmaceuticals is a biopharmaceutical company focused on kidney disease therapies. Its core product AP301, an oral phosphate binder for hyperphosphatemia, has completed China Phase III registration trials and is expected to file for NDA approval in the near term.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09637","symbol_name":"礼邦医药-B","start_time":0,"source_url":"","article_id":"1108778007","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108778007","pubTimestamp":1783301887,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 6, Alebund Pharmaceuticals-B (09637.HK) declined 8.32% in regular trading, trading at 28.22 HKD/share, with turnover of approximately 2 million HKD.The decline represents a continuation of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09637":"礼邦医药-B"},"translate_title":"异动快讯|艾利邦制药-B常规交易跌8.32%首日翻倍后IPO后回调延续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09637":1},"content_text":"On July 6, Alebund Pharmaceuticals-B (09637.HK) declined 8.32% in regular trading, trading at 28.22 HKD/share, with turnover of approximately 2 million HKD.The decline represents a continuation of post-IPO volatility. The company listed on the Hong Kong Stock Exchange on June 29 at an offer price of 22.60 HKD, surging 103.54% on its debut to close at 46.00 HKD. The stock subsequently experienced a sharp correction, falling over 50% intraday on July 2 before rebounding approximately 18.75% on July 3. Notable institutional support emerged on listing day, with Singapore's GIC increasing its stake by 872,000 shares at 44.08 HKD each, and LAV Asset Management purchasing 450,000 shares at 45.06 HKD, totaling approximately 58.72 million HKD in combined investment.Alebund Pharmaceuticals is a biopharmaceutical company focused on kidney disease therapies. Its core product AP301, an oral phosphate binder for hyperphosphatemia, has completed China Phase III registration trials and is expected to file for NDA approval in the near term.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108778007","isCrawlerRequest":true}